HeartBeam Names Ken Persen as Chief Technology Officer
SANTA CLARA, California–(BUSINESS THREAD)–HeartBeam, Inc. (NASDAQ: BEAT), a growth-stage digital health company with proprietary ECG telemedicine technology for heart attack detection, today announced the appointment of Ken Persen as Chief Technology Officer. Persen has extensive technology, executive and start-up experience in the healthcare and cardiac device industries. He will lead the global technology strategy and development of the HeartBeam AIMI™ and HeartBeam AIMIGo™ platforms.
“I am very excited to join the HeartBeam team and lead the development of the first-of-its-kind remote 3D vector electrocardiogram technology,” said Persen. “The promise of HeartBeam’s technology to substantially change the way patients and healthcare professionals manage heart attack symptoms is even more compelling.”
Persen has over 25 years of experience in the digital healthcare and cardiac device industry. Most recently, Persen founded LIVMOR, Inc. a digital health company, where he served as chief technology officer. Persen began his career in the cardiac pacemaker industry in software engineering and development roles with Guidant Corporation and Cameron Health, both later acquired by Boston Scientific, and later held leadership roles with instruments and medical IT systems that offer electronic medical assistance, before founding LIVMOR.
“We are very pleased to welcome Ken to our leadership team,” said Branislav Vajdic, Ph.D. CEO and founder of HeartBeam. “He brings a deep knowledge of innovation and technology, combined with industry knowledge, that will support the continued development and evolution of HeartBeam’s technology.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a growth-stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high-risk cardiovascular patients are diagnosed in an ambulatory setting anytime, anywhere. Their innovative solution uses a reusable credit card-sized 3D vector ECG recording device and cloud-based software capable of helping a physician diagnose a wide range of cardiovascular diseases. HeartBeam is initially focusing on a huge unmet need to help diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of coronary artery disease patients at high risk of heart attack. For more information, visit www.heartbeam.com.
All statements in this release that are not based on historical facts are “forward-looking statements.” Although management has based the forward-looking statements included in this release on its current expectations, the information on which those expectations were based may change. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors, including the risks and uncertainties described in Risk Factors and Management’s Financial Discussion and Analysis. Terms and results of our operations sections in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider these risks and uncertainties when evaluating our forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as otherwise required by federal securities laws, we disclaim any obligation or commitment to publicly release any updates or revisions to any forward-looking statements contained herein (or elsewhere) to reflect any changes in our expectations with respect thereto or any changes in the events. , conditions or circumstances on which this statement is based.